Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Notes Payables (2017 - 2025)

Historic Notes Payables for Regen BioPharma (RGBPP) over the last 10 years, with Q4 2025 value amounting to $968014.0.

  • Regen BioPharma's Notes Payables rose 80041.95% to $968014.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $968014.0, marking a year-over-year increase of 80041.95%. This contributed to the annual value of $1.0 million for FY2025, which is 10730.08% up from last year.
  • As of Q4 2025, Regen BioPharma's Notes Payables stood at $968014.0, which was up 80041.95% from $1.0 million recorded in Q3 2025.
  • Regen BioPharma's Notes Payables' 5-year high stood at $1.0 million during Q3 2025, with a 5-year trough of $1000.0 in Q1 2021.
  • For the 5-year period, Regen BioPharma's Notes Payables averaged around $187866.0, with its median value being $1000.0 (2021).
  • As far as peak fluctuations go, Regen BioPharma's Notes Payables changed by 0.0% in 2021, and later skyrocketed by 7773800.0% in 2025.
  • Quarter analysis of 5 years shows Regen BioPharma's Notes Payables stood at $1000.0 in 2021, then changed by 0.0% to $1000.0 in 2022, then soared by 4821.0% to $49210.0 in 2023, then soared by 118.47% to $107507.0 in 2024, then surged by 800.42% to $968014.0 in 2025.
  • Its last three reported values are $968014.0 in Q4 2025, $1.0 million for Q3 2025, and $778380.0 during Q2 2025.